Sirolimus
Pharmaceutical drug
Ratings
0
Nobody has rated this yet. Be the first!
Rapamycin fed late in life extends lifespan in genetically heterogeneous mice
Sirolimus therapy for a patient with segmental overgrowth due to a mosaic activating mutation in phosphatidylinositol-3-kinase
Nucleolar Disruption in Dopaminergic Neurons Leads to Oxidative Damage and Parkinsonism through Repression of Mammalian Target of Rapamycin Signaling
A comparison of the effect of ciclosporin and sirolimus on the pharmokinetics of mycophenolate in renal transplant patients
AMP-activated protein kinase suppresses protein synthesis in rat skeletal muscle through down-regulated mammalian target of rapamycin (mTOR) signaling
Calcineurin inhibitors and rapamycin: cancer protection or promotion?
